News Viatris Inc.

Equities

VTRS

US92556V1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
11.72 ^USD	-0.85%		+1.30%	+8.22%

Apr. 18	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
Apr. 18	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viatris to Participate in the BofA Securities 2024 Health Care Conference	May. 02	PR
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health	May. 01	PR
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	Apr. 18	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	Apr. 18	MT
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 16	PR
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Viatris Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	PR
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	CI
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	Apr. 15	AQ
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05	RE
Pharma deal could reduce choice and lead to higher prices for HRT treatments	Apr. 04	AQ
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	Apr. 04	MT
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04	RE
Viatris Announces the Launch of RYZUMVl 0.75% in the United States	Apr. 02	AQ
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Viatris Inc.

Equities

VTRS

US92556V1061

Summary

Filters